Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update
    Meeting Abstract

    Wong, D. J.; Schneider, J. G.; Aljumaily, R.; Korn, M. W.; Autio, K.; Infante, J. R.; Patel, M. R.; Papadopoulos, K.; Naing, A.; Gabrail, N.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
    Meeting Abstract

    Scher, H.; Graf, R. P.; Jendrisak, A.; McLaughlin, B.; Barnett, E.; Schreiber, N. A.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)
    Meeting Abstract

    Petrylak, D.; Vogelzang, N. J.; Fradet, Y.; Bajorin, D.; de Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Climent, M. A.; Necchi, A.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Powles, T.; McDermott, D. F.; Rini, B.; Motzer, R. J.; Atkins, M. B.; Fong, L.; Joseph, R. W.; Pal, S. K.; Ravaud, A.; Bracarda, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Sequential chemo-chemoradiation (CCRT) in locally advanced pancreas cancer in an Irish high volume centre
    Meeting Abstract

    Abdul Rahman, R.; Teo, M. Y.; Moriarty, M.; McDermott, R.; McVey, G.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
    Meeting Abstract

    Powles, T.; Motzer, R. J.; George, D. J.; Jonasch, E.; Pal, S.; Tannir, N. M.; Signoretti, S.; Mai, T. H.; Scheffold, C.; Wang, E.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M.; Vogelzang, N. J.; Sartor, O.; Armour, A.; Groaning, M.; Messmann, R.; Robarts, A.; Petrylak, D. P.; Tolcher, A.; Gordon, M. S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer
    Meeting Abstract

    Naing, A.; Infante, J. R.; Wong, D. J.; Korn, M. W.; Aljumaily, R.; Papadopoulos, K.; Autio, K.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study
    Meeting Abstract

    Necchi, A.; Joseph, R. W.; Loriot, Y.; Hoffman-Censits, J.; Perez Gracia, J. L.; Petrylak, D. P.; Zhu, Q.; Ding, B.; Kaiser, C.; Rosenberg, J. E.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population
    Meeting Abstract

    Necchi, A.; Pond, G. R.; Pal, S. K.; Agarwal, N.; Bowles, D.; Plimack, E.; Yu, E. Y.; Ladoire, S.; Baniel, J.; Crabb, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save